News

Burnet looking forward on World Sepsis Day

Burnet Institute

13 September, 2018

Worldsepsisday 510x288

On World Sepsis Day 2018, Burnet Institute’s commitment to addressing this illness, which kills from 7-9 million people globally each year, and more than 3000 Australians, is stronger than ever.

Sepsis is the body’s extreme response to an infection. It is a medical emergency, and unless quickly treated, it can lead to tissue damage, organ failure, and death.

And the rate of death – one person every 3.5 seconds – is overwhelming.

Burnet is playing an important and growing role, not only in Australia and regionally, but globally, with a broad range of sepsis projects, research, diagnostic development, and other initiatives that are making a significant contribution to life saving testing and treatment.

These include the development of a rapid point-of-care test with high sensitivity for the diagnosis of sepsis, which has attracted a Development Grant from the National Health and Medical Research Council, support from the Victorian Medical Research Acceleration Fund, and a Longitude Prize Discovery Award, as well as philanthropic support.

Co-Head of Burnet’s Global Diagnostics Laboratory, Associate Professor David Anderson is excited about the potential for this highly effective diagnostic, which follows the earlier discovery of a new biomarker for sepsis.

“We thought initially that we could make a test that would work around 80 percent of the time, which in itself could make a big difference, particularly in low- and middle-income countries,” Associate Professor Anderson said.

Image: Associate Professor David Anderson, PhD student Riya Palchaudhuri and Ms Mary Garcia

“But a discovery during (laboratory member) Riya Palchaudhuri’s PhD study made us realise that we actually have something that could work 97 percent of the time, which changed our thinking entirely about how we take the development of the POC test forward.”

“All of that together has led us to identifying this project as one that’s going into our qDOS Lab accelerator program to ensure the fastest possible development of a final test that could potentially save millions of lives.”

Complementing this project is Dr Naomi Spotswood’s PhD study into neonatal sepsis, and how the diagnostic could be applied in neonatal populations.

Another example of Burnet’s work in the field is a new study focused in Papua New Guinea into the use of chlorhexidine for umbilical chord care which dramatically reduces sepsis in newborns.

“Our international development people have long recognised that sepsis is one of the big killers of people and especially neonates and young children in the developing world,” Associate Professor Anderson said.

“Chris Morgan has been working with the World Health Organization to improve the care of infections in young children to stop the development of sepsis, and this is a great example of the way Burnet’s public health and life science streams can work together on life-saving projects.”

Find out more about Burnet’s work in sepsis.

Contact Details

For more information in relation to this news article, please contact:

Associate Professor David Anderson

Deputy Director (Partnerships), Burnet Institute; Co-Head, Global Health Diagnostics Development

Telephone

+61392822239

Email

david.anderson@burnet.edu.au

Subscribe to News

Subscribe to receive our latest news: